| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | BCAM; BCT2; PP18; BCATM |
| WB Predicted band size | 44 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human BCAT2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于BCAT2抗体的3篇参考文献及其摘要概述：
---
1. **文献名称**：*BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma*
**作者**：Ericksen, R.E. et al.
**摘要**：该研究通过免疫组化(使用BCAT2抗体)和代谢组学分析，发现BCAT2在胰腺导管腺癌(PDAC)中高表达，其介导的支链氨基酸(BCAA)代谢促进肿瘤生长和能量供应，靶向BCAT2可抑制癌细胞增殖。
---
2. **文献名称**：*Branched-chain amino acid transaminase 2 regulates ferroptotic cell death in cancer cells*
**作者**：Lee, H. et al.
**摘要**：研究利用BCAT2抗体进行Western blot和免疫荧光实验，证明BCAT2通过调控谷胱甘肽代谢影响铁死亡(ferroptosis)过程，在结直肠癌细胞中抑制BCAT2可增强铁死亡敏感性，为癌症治疗提供新靶点。
---
3. **文献名称**：*BCAT2 is a novel mediator of apoptosis resistance in chronic myeloid leukemia*
**作者**：Hattori, A. et al.
**摘要**：该文献通过BCAT2抗体检测白血病细胞系中的蛋白表达，发现BCAT2通过维持线粒体功能抑制细胞凋亡，敲低BCAT2可增强伊马替尼(imatinib)的药物疗效，提示其作为白血病耐药性标志物的潜力。
---
以上研究均基于BCAT2抗体在实验中的应用，涵盖肿瘤代谢、细胞死亡调控及药物抵抗机制等领域。
The BCAT2 (Branched-Chain Amino Acid Transaminase 2) antibody is a tool used to detect and study the BCAT2 protein, a key enzyme in branched-chain amino acid (BCAA) metabolism. BCAT2. also known as mitochondrial BCAT, catalyzes the transamination of BCAAs (leucine, isoleucine, valine) to their corresponding α-keto acids, a critical step in both BCAA catabolism and nitrogen homeostasis. This enzyme is expressed in mitochondria-rich tissues, including skeletal muscle, heart, and brain, and plays roles in energy production, neurotransmitter synthesis (e.g., glutamate), and mTOR pathway regulation.
Research on BCAT2 has gained attention due to its involvement in metabolic disorders, neurodegenerative diseases, and cancer. Dysregulated BCAA metabolism is linked to insulin resistance, while elevated BCAT2 expression has been observed in gliomas and other cancers, where it may support tumor growth via metabolic reprogramming. BCAT2 antibodies enable the detection of protein expression levels, subcellular localization, and post-translational modifications in experimental models. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Commercial BCAT2 antibodies are typically raised in rabbits or mice against specific epitopes, with validation in knockout controls to ensure specificity. Ongoing studies focus on BCAT2's therapeutic potential, making its antibody a vital reagent for mechanistic and translational research.
×
